In this issue:
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with advanced pancreatic cancer
Epidermal growth factor receptor inhibition in amplified gastroesophageal cancer
The risk of pancreatic cancer based on the lifestyle, body mass index, diabetes
Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms
Genetic variants involved in the cGAS-STING pathway and outcomes of metastatic colorectal cancer
Prognostic impact of performance status in patients with dMMR/MSI-H metastatic colorectal cancer
Lurbinectedin in patients with pre-treated neuroendocrine tumours
Three-year follow up and response-survival relationship of nivolumab in squamous cell carcinoma
Efficacy and safety of regorafenib therapy for patients with refractory metastatic colorectal cancer
Treatment and outcomes of unresectable and metastatic pancreatic cancer
Please login below to download this issue (PDF)